First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light-Reference-Cited by-同舟云学术

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

Published:2019-08 Issue: Volume:134 Page:245-253
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ackermann Christoph Jakob,Reck Martin,Paz-Ares Luis,Barlesi Fabrice,Califano Raffaele^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference49 articles.

1. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro);Herbst;Ann. Oncol.,2018

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review;Cancer Cell International;2024-01-05

2. Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%;BMC Cancer;2023-08-23

3. A Cellular Senescence-Related Signature Predicts Cervical Cancer Patient Outcome and Immunotherapy Sensitivity;Reproductive Sciences;2023-08-14

4. Network Meta-Analysis of First-Line Immune Checkpoint Inhibitor Therapy in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with PD-L1 Expression ≥50%;2023-05-08

5. A Cellular Senescence-Related Signature Predicts Cervical Cancer Patient Outcome and Immunotherapy Sensitivity;2023-04-20